FENSOLVI Drug Patent Profile
✉ Email this page to a colleague
When do Fensolvi patents expire, and when can generic versions of Fensolvi launch?
Fensolvi is a drug marketed by Tolmar and is included in one NDA. There are three patents protecting this drug.
The generic ingredient in FENSOLVI is leuprolide acetate. There are twenty-two drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fensolvi
A generic version of FENSOLVI was approved as leuprolide acetate by SANDOZ on August 4th, 1998.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for FENSOLVI?
- What are the global sales for FENSOLVI?
- What is Average Wholesale Price for FENSOLVI?
Summary for FENSOLVI
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for FENSOLVI |
| What excipients (inactive ingredients) are in FENSOLVI? | FENSOLVI excipients list |
| DailyMed Link: | FENSOLVI at DailyMed |
US Patents and Regulatory Information for FENSOLVI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tolmar | FENSOLVI KIT | leuprolide acetate | POWDER;SUBCUTANEOUS | 213150-001 | May 1, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Tolmar | FENSOLVI KIT | leuprolide acetate | POWDER;SUBCUTANEOUS | 213150-001 | May 1, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Tolmar | FENSOLVI KIT | leuprolide acetate | POWDER;SUBCUTANEOUS | 213150-001 | May 1, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |


